文献速递前列腺癌

卡博替尼对比米托蒽醌-泼尼松治疗有症状转移性去势抵抗性前列腺癌:以疼痛为主要终点的随机3期试验

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
PubMed 文献 · Eur Urol · 2018-12-04

COMET-2是一项随机双盲3期试验,比较卡博替尼与米托蒽醌-泼尼松在有症状骨转移的mCRPC患者中的疼痛缓解。因COMET-1无生存获益而提前终止,实际随机119例。第6周疼痛反应经第12周确认的比例卡博替尼15% vs 米托蒽醌-泼尼松17%,差异-2%(95%CI -16%至11%,p=0.8),无显著差异。

要点

  • 卡博替尼未显示优于米托蒽醌-泼尼松的疼痛缓解。
  • 疼痛反应率15% vs 17%,差异无统计学意义。
  • 试验因同伴研究无生存获益而提前终止。

核心结论

  • 在重度经治的mCRPC伴症状性骨转移患者中,卡博替尼的疼痛缓解未优于米托蒽醌-泼尼松。

研究设计与样本

  • 随机双盲3期试验(COMET-2;NCT01522443),计划样本量246例,实际随机119例(卡博替尼61例,米托蒽醌-泼尼松58例)。

主要发现

  • 卡博替尼组疼痛反应者比例为15%,米托蒽醌-泼尼松组为17%,差异-2%(95%CI -16%至11%,p=0.8)。
  • 基线、第6周和第12周完整疼痛及麻醉药使用数据可用于73/106(69%)患者。

关键数值与推荐

  • 主要终点为第6周疼痛反应并经第12周确认,定义为Brief Pain Inventory患者报告的每日最痛评分较基线下降≥30%且麻醉药使用未增加。
  • 卡博替尼60mg每日一次口服,对比米托蒽醌12mg/m2每3周一次加泼尼松5mg每日两次口服。

临床怎么用

  • 对于重度经治的mCRPC伴症状性骨转移患者,卡博替尼不应作为优于米托蒽醌-泼尼松的疼痛缓解选择。

局限性

  • 因COMET-1无生存获益而提前终止入组,实际样本量远低于计划。
  • 仅69%患者有完整的基线、第6周和第12周疼痛及麻醉药使用数据。
  • 入组障碍包括既往抗癌治疗洗脱期和麻醉药优化期等预处理要求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) are associated with debilitating pain and functional compromise. OBJECTIVE: To compare pain palliation as the primary endpoint for cabozantinib versus mitoxantrone-prednisone in men with mCRPC and symptomatic bone metastases using patient-reported outcome measures. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind phase 3 trial (COMET-2; NCT01522443) in men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with docetaxel and either abiraterone or enzalutamide. INTERVENTION: Cabozantinib 60mg once daily orally versus mitoxantrone 12mg/m2 every 3wk plus prednisone 5mg twice daily orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was pain response at week 6 confirmed at week 12 (≥30% decrease from baseline in patient-reported average daily worst pain score via the Brief Pain Inventory without increased narcotic use). The planned sample size was 246 to achieve ≥90% power. RESULTS AND LIMITATIONS: Enrollment was terminated early because cabozantinib did not demonstrate a survival benefit in the companion COMET-1 trial. At study closure, 119 participants were randomized (cabozantinib: N=61; mitoxantrone-prednisone: N=58). Complete pain and narcotic use data were available at baseline, week 6, and week 12 for 73/106 (69%) patients. There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8). Barriers to accrual included pretreatment requirements for a washout period of prior anticancer therapy and a narcotic optimization period to maximize analgesic dosing. CONCLUSIONS: Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases. Future pain-palliation trials should incorporate briefer timelines from enrollment to treatment initiation. PATIENT SUMMARY: Cabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Basch EM, Scholz M, de Bono JS, et al. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. Eur Urol. 2018. PMID: 30528222. doi:10.1016/j.eururo.2018.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。